NCT04537806View on ClinicalTrials.gov

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

PHASE3TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Acute Respiratory Distress SyndromeCOVID-19
Interventions
DRUG

Brexanolone

Administered as IV infusion.

DRUG

Placebo

Administered as IV infusion.

Trial Locations (9)

23298

Sage Investigational Site, Richmond

28203

Sage Investigational Site, Charlotte

30912

Sage Investigational Site, Augusta

48912

Sage Investigational Site, Lansing

89102

Sage Investigational Site, Las Vegas

93701

Sage Investigational Site, Fresno

98122

Sage Investigational Site, Seattle

02115

Sage Investigational Site, Boston

01805

Sage Investigational Site, Burlington

Sponsors

Lead Sponsor

Sage Therapeutics
All Listed Sponsors
lead

Sage Therapeutics

INDUSTRY

NCT04537806 - A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter